Frequency News and Research

RSS

Medicare drug spending varies by region, does not offset other medical costs

A study has found that Medicare spending on drugs varies significantly in different regions, and that increased drug spending isn't offset by lower spending on hospital care, doctors visits and other health services, HealthDay/Bloomberg Businessweek reports.

11 Jun 2010

Researchers to provide real-time analyses on potential disease threats during World Cup

Two Canadian researchers will be keeping a close eye on what hundreds of thousands of soccer fans take to the World Cup in South Africa _ and what they potentially bring home.

11 Jun 2010

Nativis awarded patents in Japan, China, India for drug signal technology

Nativis, Inc., a La Jolla, Calif.-based life science company, has been issued patents in Japan, China and India for its innovative technology that captures the unique signals of approved drugs at the atomic level and then delivers the signal in a solution to treat serious illnesses. The technology, which also has U.S., Canadian and Australian patents, promises to transform the treatment of diseases, including those for which there are no known cures, such as brain cancer.

10 Jun 2010

People who smoke immediately after waking may be at risk for lung cancer: Study

People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smoke, regardless of the number of cigarettes smoked.

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary hepatocellular cancer including those with disease that has spread outside the liver, according to the results of a prospective clinical study presented today at the 46th American Society of Clinical Oncology conference.

10 Jun 2010

Medicalis launches Coordinated Imaging Care Solution

Medicalis Corporation announced today the launch of its Coordinated Imaging Care Solution (CICS), an integrated technology platform that provides clinical decision support, e-ordering, and extensive quality tracking that enables comparative effectiveness in medical imaging. The solution provides the broadest set of quality indicators specifically related to medical imaging available.

9 Jun 2010

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.

9 Jun 2010

HHS Secretary statement on new study that underscores urgency for reducing HAIs in ASCs

"Today, the Journal of the American Medical Association published a new study from the Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services, which underscored the urgency behind the Obama Administration's efforts to reduce healthcare-associated infections.

9 Jun 2010

FDA should implement risk-based approach to tackle food safety problems: Report

The U.S. Food and Drug Administration's abilities to discover potential threats to food safety and prevent outbreaks of foodborne illness are hampered by impediments to efficient use of its limited resources and a piecemeal approach to gathering and using information on risks, says a new report by the Institute of Medicine and National Research Council.

9 Jun 2010

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

Columbia Laboratories, Inc. today announced it completed enrollment in the PREGNANT (PROCHIEVE Extending GestatioN A New Therapy) Study last week. This randomized, double-blind, placebo controlled Phase III clinical study is evaluating the safety and efficacy of PROCHIEVE® 8% (progesterone gel) to reduce the risk of preterm birth in women with a cervical length between 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy.

8 Jun 2010

Nighttime noise disturbs sleep, impairs neurobehavioral performance in the morning: Research

Nighttime noise from nearby road traffic, passing trains and overhead planes disturbs sleep and impairs morning performance, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.

8 Jun 2010

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

PhotoMedex, Inc. announced today that John Koo, MD will be the principal investigator in a clinical study assessing the efficacy of the XTRAC Velocity® excimer laser in the treatment of generalized psoriasis when used in combination with Clobex® spray. Dr. Koo is Professor and Vice Chairman in the Department of Dermatology at the University of California San Francisco Medical Center. Spearheading the study will be Dr. Koo's colleague, Tina Bhutani, MD.

8 Jun 2010

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Depomed, Inc. today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

8 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

7 Jun 2010

Study identifies potential link between Gilbert's Syndrome, childhood acute lymphoblastic leukemia

Scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, both in Detroit, and the Children's Hospital of Michigan/Detroit Medical Center, presented preliminary data that identified a potential link between Gilbert's Syndrome and the development of a specific subtype of childhood acute lymphoblastic leukemia (ALL). The findings were announced today at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

ChemGenex reports positive safety findings from two OMAPRO clinical trials at ASCO 2010

ChemGenex Pharmaceuticals Limited announced that positive safety findings from a combined analysis of two clinical trials for its lead product candidate, OMAPRO™ (omacetaxine mepesuccinate), were presented today during a poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

7 Jun 2010

Encore Path signs license agreement for UMB technology that helps stroke patients redevelop natural gait

The University of Maryland, Baltimore's Office of Research and Development announced that Encore Path, Inc. of Baltimore signed an exclusive worldwide license agreement for a device technology invented jointly by researchers at the University of Maryland, Baltimore and the University of Maryland Baltimore County that helps stroke patients retrain their bodies to walk.

5 Jun 2010

Frequency News and Research

Medicare drug spending varies by region, does not offset other medical costs

Researchers to provide real-time analyses on potential disease threats during World Cup

Nativis awarded patents in Japan, China, India for drug signal technology

People who smoke immediately after waking may be at risk for lung cancer: Study

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

Medicalis launches Coordinated Imaging Care Solution

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

HHS Secretary statement on new study that underscores urgency for reducing HAIs in ASCs

FDA should implement risk-based approach to tackle food safety problems: Report

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

Nighttime noise disturbs sleep, impairs neurobehavioral performance in the morning: Research

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Study identifies potential link between Gilbert's Syndrome, childhood acute lymphoblastic leukemia

ChemGenex reports positive safety findings from two OMAPRO clinical trials at ASCO 2010

Encore Path signs license agreement for UMB technology that helps stroke patients redevelop natural gait

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News